Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207804 | 0.86 | HRH4 (0.53) | HRH4HRH1TLR7TLR9HRH3 | |
| SCHEMBL3210927 | 0.78 | HRH4 (0.57) | HRH4HRH1TDP1 | |
| SCHEMBL3199636 | 0.69 | HRH4 (0.46) | HRH4HRH3 | |
| SCHEMBL606401 | 0.69 | HRH4 (0.65) | HRH4HRH3 | |
| SCHEMBL14503382 | 0.65 | GBA1 (0.49) | TDP1ALDH1A1TSHR | |
| SCHEMBL9884693 | 0.64 | CXCR4 (0.51) | ALDH1A1TSHRKMT2A | |
| SCHEMBL9885841 | 0.64 | CXCR4 (0.51) | ALDH1A1TSHRKMT2A | |
| SCHEMBL9885845 | 0.64 | CXCR4 (0.51) | ALDH1A1TSHRKMT2A | |
| SCHEMBL5094968 | 0.63 | MEN1 (0.50) | TLR7TLR9HRH3CYP3A4KCNH2 | |
| SCHEMBL22791989 | 0.63 | MAP4K4 (0.39) | TLR7TLR9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | claimed |
| EP-2066645-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB Pharma S.A. (BE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008031556-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB PHARMA, S.A. (BE) | 2008-03-20 | — | — | WO | claimed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | HRH4 1/4885HRH1 9/4885TLR7 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.